sepsis

The RT-qPCR-based assay, which has 510(k) clearance, is designed to rapidly differentiate sepsis from systemic inflammatory response syndrome.

The firm expects to use the funding to meet demand for its Steripath platform, which improves accuracy, consistency, and predictability of diagnostic lab tests.

The new regulatory approvals add to previous approvals in Singapore, expanding the firm's reach in the Association of Southeast Asian Nations region.

The firm's CEO told investors at the JP Morgan Healthcare Conference that in addition to driving growth of its sepsis test in the US, Accelerate is eyeing expansion into China.

The company expects to miss the consensus Wall Street revenue estimates for Q4 and full-year 2018.

The test is the second of three panels intended to detect pathogens that cause the bloodstream infections that can lead to sepsis.

The firm had also applied for marketing clearance for its gram negative and fungal pathogen panels in October.